Alembic Pharma gets USFDA EIR for 2 API facilities in Panelav
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-09-13 11:53 GMT | Update On 2025-09-13 11:53 GMT
Advertisement
Vadodara: Alembic Pharma has announced that the Company has received Establishment Inspection Report (EIR) for the inspection carried out by the US Food and Drug Administration (USFDA) at its API - I & API - II Facility located at Panelav.
The EIR follows the inspection conducted from 26th May, 2025 to 31st May, 2025.
During the inspection, the facilities initially received four observations. Now EIR has been issued.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.